Australian Centre for Precision Health, School of Health Sciences, The University of South Australia, Adelaide, South Australia, Australia.
School of Medicine, The University of Adelaide, Adelaide, South Australia, Australia.
PLoS One. 2020 Apr 29;15(4):e0231095. doi: 10.1371/journal.pone.0231095. eCollection 2020.
Varenicline tartrate is superior for smoking cessation to other tobacco cessation therapies by 52 weeks, in the outpatient setting. We aimed to evaluate the long-term (104 week) efficacy following a standard course of inpatient-initiated varenicline tartrate plus Quitline-counselling compared to Quitline-counselling alone.
Adult patients (n = 392, 20-75 years) admitted with a smoking-related illnesses to one of three hospitals, were randomised to receive either 12-weeks of varenicline tartrate (titrated from 0.5mg daily to 1mg twice-daily) plus Quitline-counselling, (n = 196) or Quitline-counselling alone, (n = 196), with continuous abstinence from smoking assessed at 104 weeks.
A total of 1959 potential participants were screened for eligibility between August 2008 and December 2011. The proportion of participants who remained continuously abstinent (intention-to-treat) at 104 weeks were significantly greater in the varenicline tartrate plus counselling arm (29.2% n = 56) compared to counselling alone (18.8% n = 36; p = 0.02; odds ratio 1.78; 95%CI 1.10 to 2.86, p = 0.02). Twenty-two deaths occurred during the 104 week study (n = 10 for varenicline tartrate plus counselling and n = 12 for Quitline-counselling alone). All of these participants had known or developed underlying co-morbidities.
This is the first study to examine the efficacy and safety of varenicline tartrate over 104 weeks within any setting. Varenicline tartrate plus Quitline-counselling was found to be an effective opportunistic treatment when initiated for inpatient smokers who had been admitted with tobacco-related disease.
在门诊环境下，酒石酸伐尼克兰片在戒烟方面优于其他烟草戒断疗法，在 52 周时效果显著。我们旨在评估标准疗程的住院患者起始酒石酸伐尼克兰片联合戒烟热线咨询与单纯戒烟热线咨询相比的长期（104 周）疗效。
将 392 名（年龄 20-75 岁）因吸烟相关疾病住院的成年患者随机分为两组，分别接受为期 12 周的酒石酸伐尼克兰片（从每日 0.5mg 滴定至每日 2 次，每次 1mg）联合戒烟热线咨询（n = 196）或单纯戒烟热线咨询（n = 196），在 104 周时评估连续戒烟情况。
在 2008 年 8 月至 2011 年 12 月期间，共有 1959 名潜在参与者接受了筛选以确定是否符合入选标准。在 104 周时，酒石酸伐尼克兰片联合咨询组（56 人，29.2%）持续戒烟（意向治疗）的参与者比例明显高于单纯咨询组（36 人，18.8%；p = 0.02；比值比 1.78；95%置信区间 1.10 至 2.86，p = 0.02）。在 104 周的研究期间，有 22 人死亡（酒石酸伐尼克兰片联合咨询组 10 人，戒烟热线咨询组 12 人）。所有这些参与者都有已知或发展出的潜在合并症。
这是第一项在任何环境下对酒石酸伐尼克兰片进行 104 周疗效和安全性评估的研究。对于因烟草相关疾病住院的吸烟者，在住院时开始使用酒石酸伐尼克兰片联合戒烟热线咨询，被证明是一种有效的机会性治疗方法。
